Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05028634 (ClinicalTrials.gov)	October 27, 2021	25/8/2021	Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-ß or No Disease Modifying Therapy	A Phase 3b, Multicenter, Open-label Study to Evaluate the Immune Response to, and the Safety of, Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Oral Ozanimod Compared to Non-pegylated Interferon (IFN)-ß or No Disease Modifying Therapy	Multiple Sclerosis;Multiple Sclerosis, Relapsing-Remitting	Biological: Tetanus, diphtheria, and acellular pertussis vaccine;Biological: Pneumococcal polysaccharide vaccine;Biological: Seasonal influenza vaccine	Celgene	NULL	Recruiting	18 Years	65 Years	All	60	Phase 3	United States;Germany
2	NCT05019248 (ClinicalTrials.gov)	September 1, 2020	19/8/2021	Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine	A Non-interventional Observation Study to Evaluate Immune Responses Following Seasonal Influenza Vaccine in Participants With Relapsing Multiple Sclerosis Treated With Cladribine Tablets	Multiple Sclerosis, Relapsing-Remitting;Vaccine Response Impaired	Biological: Most recent vaccine to seasonal influenza	Heinrich-Heine University, Duesseldorf	NULL	Recruiting	18 Years	60 Years	All	260		Germany
3	NCT01199861 (ClinicalTrials.gov)	August 2010	9/9/2010	Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)	A 3-month Blinded, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Influenza Vaccination and Tetanus Toxoid Booster Injection in Patients With Relapsing Forms of Multiple Sclerosis (MS)	Relapsing Multiple Sclerosis	Drug: Fingolimod;Drug: Placebo;Biological: Seasonal influenza vaccine;Biological: Tetanus toxoid vaccine	Novartis	NULL	Completed	18 Years	55 Years	All	138	Phase 3	Belgium;Canada;Finland;France;Guatemala;Poland;Spain;Switzerland;United Kingdom;Austria
4	NCT01051349 (ClinicalTrials.gov)	March 31, 2010	15/1/2010	Safety and Efficacy Extension Study of Daclizumab High Yield Process (DAC HYP) (BIIB019) in Participants Who Have Completed Study 205MS202 (NCT00870740) to Treat Relapsing Remitting Multiple Sclerosis	A Multicenter, Open-label, Extension Study to Evaluate the Long Term Safety and Efficacy of Daclizumab High Yield Process (DAC HYP) Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Treatment in Study 205MS202 (SELECTION)	Relapsing-Remitting Multiple Sclerosis	Biological: BIIB019 (Daclizumab);Biological: trivalent seasonal influenza vaccine	Biogen	AbbVie	Completed	18 Years	60 Years	All	410	Phase 2	Czechia;Germany;Hungary;India;Poland;Russian Federation;Ukraine;United Kingdom;Czech Republic